|Gebot||62,51 x 0|
|Briefkurs||62,76 x 0|
|Tagesspanne||63,26 - 63,26|
|52-Wochen-Spanne||63,26 - 63,26|
|Beta (5 J., monatlich)||0,45|
|Kurs-Gewinn-Verhältnis (roll. Hochrechn.)||23,20|
|EPS (roll. Hochrechn.)||2,70|
|Gewinndatum||27. Apr. 2023|
|Erwartete Dividende & Rendite||N/A (N/A)|
Bristol Myers Squibb has a long-standing partnership with The Leukemia & Lymphoma Society (LLS) and has been the top biopharma fundraising team for Light The Night® for more than a decade. Since 1949, the LLS has invested nearly $1.5 billion in cancer research, and has provided more than $431 million in co-pay financial assistance to patients. While Light The Night® is a U.S.-based event, it supports the LLS, which is a global leader in cancer research.
The Bristol Myers Squibb Foundation (BMSF), together with Virginia Commonwealth University (VCU), the American Association for Cancer Research (AACR) and Gilead Sciences, Inc., today announced that an additional 64 physicians have been selected to receive the Robert A.